Androgen receptor directed therapies in castration-resistant metastatic prostate cancer.
about
Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancerCastration-resistant prostate cancer: potential targets and therapies.Dysregulation of miRNAs-COUP-TFII-FOXM1-CENPF axis contributes to the metastasis of prostate cancer.Advances in androgen receptor targeted therapy for prostate cancerCombining T-cell immunotherapy and anti-androgen therapy for prostate cancer.Roles for the backdoor pathway of androgen metabolism in prostate cancer response to castration and drug treatment.Liver injury associated with ketoconazole: review of the published evidence.Leading causes of castration-resistant prostate cancer.Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide.Co-targeting androgen receptor and DNA for imaging and molecular radiotherapy of prostate cancer: in vitro studies.Enhanced inhibition of prostate tumor growth by dual targeting the androgen receptor and the regulatory subunit type iα of protein kinase a in vivoOral Azole Antifungal Medications and Risk of Acute Liver Injury, Overall and by Chronic Liver Disease Status.Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF-β1/STAT3 axis-regulated EMT.Resveratrol enhances polyubiquitination-mediated ARV7 degradation in prostate cancer cells.Androgen receptor gene mutation, rearrangement, polymorphism.Multimodal actions of the phytochemical sulforaphane suppress both AR and AR-V7 in 22Rv1 cells: Advocating a potent pharmaceutical combination against castration-resistant prostate cancer.
P2860
Q35150756-31DCC4E5-A567-44DE-B43E-7AD3E70FD0DEQ36196682-ACE16864-0686-46A3-972C-79D9B51E722FQ36845839-44918398-7D6C-47D2-86BE-C84A5B40D260Q37337217-2797E773-8281-490D-BF99-9BDA21BBEBA1Q37443603-CA3FF8AF-BFE4-42E4-B335-2AFF46FB1059Q38221851-E2C1EEF4-4693-48DC-A7E7-3E3448218091Q38248677-FF788AA7-D93B-4169-9F1E-E311B2DCF755Q38341864-F556470E-07C4-4FCC-B7D0-F0C56B144681Q38754074-D2C365D5-ABFF-45DF-B35D-1884906E950EQ38957279-653A5627-816A-4D4D-9AFE-87E2CF18EEBBQ39143940-64882107-D99C-4DFF-AA2D-BCE300C6EC83Q40898783-6E4F21ED-7272-48DA-9521-D0ED0C1961BAQ41167484-FB93E575-5A99-4536-B646-D0E9BEB0E7FCQ41551014-4C4EEA30-1B19-4CC2-A867-DCBC9782BC6FQ42738421-B15A2D04-790C-493F-B3E4-AA5EC9662039Q47811299-1433CF5D-5E4C-43B0-83EC-C50765EC209E
P2860
Androgen receptor directed therapies in castration-resistant metastatic prostate cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Androgen receptor directed therapies in castration-resistant metastatic prostate cancer.
@en
type
label
Androgen receptor directed therapies in castration-resistant metastatic prostate cancer.
@en
prefLabel
Androgen receptor directed therapies in castration-resistant metastatic prostate cancer.
@en
P2860
P1476
Androgen receptor directed therapies in castration-resistant metastatic prostate cancer.
@en
P2093
Charles J Ryan
P2860
P2888
P304
P356
10.1007/S11864-012-0188-2
P577
2012-06-01T00:00:00Z
P6179
1001754589